IL2RA and asthma: In line with this Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation [40] and daclizumab, a monoclonal antibody directed against CD25 subunit of IL2-R, improves asthma control in patients with moderate to severe persistent asthma [41].